Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 19/20 | 0.37 |
| ▸ | LGALS1 | P09382 | 3/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22821501 | 0.85 | LGALS3 (0.38) | LGALS3LGALS1HSP90AA1HSP90AB1 | |
| SCHEMBL20868458 | 0.78 | GSK3B (0.39) | LGALS3LGALS1 | |
| SCHEMBL20812240 | 0.76 | PTGS2 (0.47) | HSP90AA1HSP90AB1 | |
| SCHEMBL15835844 | 0.75 | CHRNB2 (0.47) | LGALS3LGALS1 | |
| SCHEMBL23346361 | 0.74 | LGALS3 (0.39) | LGALS3LGALS1 | |
| SCHEMBL25494292 | 0.73 | FLT3 (0.46) | — | |
| SCHEMBL26156421 | 0.71 | CYP19A1 (0.45) | — | |
| SCHEMBL22821299 | 0.71 | LGALS3 (0.39) | LGALS3LGALS1 | |
| SCHEMBL25525236 | 0.69 | MAPT (0.40) | HSP90AA1HSP90AB1 | |
| SCHEMBL20812238 | 0.69 | HSP90AA1 (0.55) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | GLYCOMIMETICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | GLYCOMIMETICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11548908-B2 | Heterobifunctional inhibitors of E-selectin and galectin-3 | GLYCOMIMETICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20200399301-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTIN AND GALECTIN-3 | GLYCOMIMETICS, INC. (US) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399301-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTIN AND GALECTIN-3 | LGALS3, LGALS3BP, LGALS1 | LGALS3 1/4885LGALS1 3/4885HSP90AA1 1533/4885 |
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | LGALS3, LGALS3BP, LGALS1 | LGALS3 1/4885LGALS1 3/4885HSP90AA1 2153/4885 |
| US-11548908-B2 | Heterobifunctional inhibitors of E-selectin and galectin-3 | LGALS3, LGALS3BP, LGALS1 | LGALS3 1/4885LGALS1 3/4885HSP90AA1 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.